Associate Professor of Anesthesiology Emory University Hospital Atlanta, Georgia
Disclosure(s): No relevant financial relationship(s) to disclose.
Disclosure(s):
Craig S. Jabaley, MD, FCCM: No relevant financial relationship(s) to disclose.
Rapid bedside identification of biomarkers is not yet available. There is mounting evidence that biologic phenotype predicts treatment response. Analyzing the hypo- and hyper-inflammatory phenotypes have been observed to have differential treatment responses to several different interventions, including ventilator, fluid management, and pharmacologic strategies. The use of translational medicine and gene therapies are on the forefront as potential targeted therapies for this devastating disease. This presentation will put all of the pieces together, revealing how genomic research into other diseases have changed the landscape of medicine while showing the path for future research requirements and potential for revelational therapies to treat ARDS.
Presentations in this session: Physiologic Sub-phenotypes in ARDS: Can They Make A Difference? - Carolyn Calfee, MD, MS Don't Be So Inflammatory: Understanding Biologic Inflammatory Sub-Phenotypes in ARDS - Jennifer Wilson, MD, MS Mixing It Together: Recipe for Translational And Genomic Target Therapies Sub-phenotypes in ARDS - Craig S. Jabaley, MD, FCCM
